van Houte Hans 4
4 · Nurix Therapeutics, Inc. · Filed Apr 30, 2026
Research Summary
AI-generated summary of this filing
Nurix (NRIX) CFO Hans van Houte Exercises RSUs, Sells 2,388 Shares
What Happened
- Hans van Houte, CFO of Nurix Therapeutics (NRIX), had RSUs convert to common shares on 2026-04-30 (three separate partial vesting events totaling 8,608 shares at $0 cost) and sold 2,388 shares in an open-market sell-to-cover transaction for proceeds of $39,749 (weighted average price $16.65).
- The conversion entries are reported as derivative exercises (transaction code M) because each RSU converts into one share on vesting; the sale was routine tax-withholding (not a discretionary market sale).
Key Details
- Transaction date: 2026-04-30.
- Conversion (exercise) of RSUs: 2,000 + 3,750 + 2,858 = 8,608 shares acquired at $0.00 (code M).
- Open-market sale: 2,388 shares sold at a weighted average price of $16.65 for total proceeds of $39,749. Reported sale price range: $16.51–$16.78 (footnote F2).
- Footnotes: F1 states the sale was a mandatory "sell-to-cover" to satisfy tax withholding on RSU vesting (not a discretionary trade). F3–F7 describe that each RSU equals one share and list vesting schedules (1/12 quarterly over three years for the awards).
- Shares owned after the transactions are not specified in the provided filing.
- No late filing flag is indicated in the summary information.
Context
- This is a typical cashless/sell-to-cover event following RSU vesting: RSUs converted to shares (exercise/conversion) and a portion sold immediately to pay required taxes. Such transactions are routine and do not necessarily indicate a change in insider sentiment.
Insider Transaction Report
Form 4
van Houte Hans
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2026-04-30+2,000→ 47,427 total - Exercise/Conversion
Common Stock
2026-04-30+3,750→ 51,177 total - Exercise/Conversion
Common Stock
2026-04-30+2,858→ 54,035 total - Sale
Common Stock
[F1][F2]2026-04-30$16.65/sh−2,388$39,749→ 51,647 total - Exercise/Conversion
Restricted Stock Units
[F3][F4][F5]2026-04-30−2,000→ 0 totalExercise: $0.00→ Common Stock (2,000 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F6][F5]2026-04-30−3,750→ 15,000 totalExercise: $0.00→ Common Stock (3,750 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F7][F5]2026-04-30−2,858→ 22,867 totalExercise: $0.00→ Common Stock (2,858 underlying)
Footnotes (7)
- [F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- [F2]Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- [F3]Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- [F4]The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F5]RSUs do not expire; they either vest or are canceled prior to the vest date.
- [F6]The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- [F7]The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte|2026-04-30